MetaVia Inc. (MTVA)

In early December 2025, MetaVia's stockholders approved a 1-for-11 reverse stock split to address Nasdaq's minimum bid price requirement, and the company subsequently regained compliance with Nasdaq's listing rules. In January 2026, MetaVia reported positive data from the Phase 1 extended 8-week cohort of DA-1726, demonstrating significant weight loss, improved glucose control, and reduced liver stiffness. In January 2026, MetaVia closed an underwritten public offering, raising approximately $9.3 million in gross proceeds, expected to fund operations into the fourth quarter of 2026. In March 2026, MetaVia reported its full-year 2025 financial results, showing a reduced net loss of $12.97 million compared to $27.59 million in 2024. In March 2026, the company received IRB approval for higher-dose Phase 1 studies of DA-1726, with dosing commencing in April 2026 and data anticipated in the fourth quarter of 2026. MetaVia expanded its global patent protection for Vanoglipel (DA-1241) through 2035 and for DA-1726 through 2041. Between April 2, 2025, and April 1, 2026, MetaVia's stock price experienced a significant decline, and analyst price targets have also seen decreases.

As a clinical-stage biotechnology company, MetaVia, Inc. does not currently have commercialized products or services that are subject to traditional market demand seasonality. The company's demand is primarily driven by investor interest, influenced by the progress and outcomes of its clinical trials, regulatory milestones, and overall market sentiment towards the biotechnology and cardiometabolic disease sectors. The available information does not indicate any specific seasonal patterns related to the progress of its clinical trials or regulatory approvals.

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases, operating within the Healthcare sector, specifically in the Biotechnology & Drugs industry. Its primary focus is on drug candidates DA-1726, a novel oxyntomodulin analogue for obesity and MASH, and DA-1241 (Vanoglipel), a novel GPR119 agonist for MASH and T2DM. The company also has legacy therapeutic programs, including ANA001, NB-01, NB-02, and Gemcabene. As a clinical-stage company, MetaVia's business model is centered on research and development, and it does not currently generate product revenue.

MetaVia, Inc. is incorporated in Delaware and maintains its principal offices in Cambridge, Massachusetts. The company's operational footprint is primarily domestic, with international activities limited to utilizing global clinical research organizations and trial sites when necessary for clinical development. It does not report significant international commercial operations or manufacturing facilities.

MetaVia, Inc.'s brand reputation has been shaped by its strategic repositioning and clinical advancements. The company rebranded from NeuroBo Pharmaceuticals Inc. to MetaVia Inc. in November 2024, refocusing on cardiometabolic diseases. Positive clinical trial results for DA-1726 and DA-1241 have likely contributed positively to its scientific and medical reputation. However, the significant decline in stock price and analyst price target decreases could impact investor perception and broader market reputation.

MetaVia, Inc. has a number of major institutional and individual owners. As of April 8, 2026, there were 13 institutional owners holding a total of 36,338 shares, including Vanguard Group Inc., Citadel Advisors Llc., Morgan Stanley, UBS Group AG, and BlackRock, Inc. Among individual shareholders, Andrew Koven is noted as owning the most shares of MetaVia, and Dong-A ST Co Ltd is also listed as a significant insider shareholder.